{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:33:27Z","timestamp":1791236007813,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.tips.2013.03.002","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T01:17:42Z","timestamp":1365556662000},"page":"261-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["The case for soluble A\u03b2 oligomers as a drug target in Alzheimer's disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Franz","family":"Hefti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Goure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Jerecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent S.","family":"Iverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Walicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"Krafft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2013.03.002_bib0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12603-013-0002-2","article-title":"2012: A watershed year for Alzheimer's disease research","volume":"17","author":"Grundman","year":"2013","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.tips.2013.03.002_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/exnr.1995.1080","article-title":"Clusterin inhibits aggregation of \u03b2-amyloid protein and forms a soluble complex that causes oxidative stress","volume":"136","author":"Oda","year":"1995","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2013.03.002_bib0015","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u03b21\u201342 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.03.002_bib0020","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1074\/jbc.271.8.4077","article-title":"Water-soluble A\u03b2 (N-40, N-42) oligomers in normal and Alzheimer disease brains","volume":"271","author":"Kuo","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.03.002_bib0025","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.1834302100","article-title":"Alzheimer's disease-affected brain: presence of oligomeric A\u03b2 ligands (ADDLs) suggests a molecular basis for reversible memory loss","volume":"100","author":"Gong","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.03.002_bib0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-\u03b2 protein assembly in the brain impairs memory","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nat. Lett."},{"key":"10.1016\/j.tips.2013.03.002_bib0035","doi-asserted-by":"crossref","first-page":"e32014","DOI":"10.1371\/journal.pone.0032014","article-title":"Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation","volume":"7","author":"Sehlin","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2013.03.002_bib0040","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid \u03b2-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.03.002_bib0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic A\u03b2 oligomer and Alzheimer's disease: an emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nsmb.1799","article-title":"Structural conversion of neurotoxic amyloid-\u03b21-42 oligomers to fibrils","volume":"17","author":"Ahmed","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2013.03.002_bib0055","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1523\/JNEUROSCI.5721-09.2010","article-title":"Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies","volume":"30","author":"Hillen","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0060","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.1237107100","article-title":"Spherical aggregates of amyloid \u03b2 (amylospheroid) show high neurotoxicity and activate tau protein kinase I\/glycogen synthase-3\u03b2","volume":"100","author":"Hoshi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.03.002_bib0065","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1523\/JNEUROSCI.0203-11.2011","article-title":"Soluble A\u03b2 oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors","volume":"31","author":"Li","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0070","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1074\/jbc.M210207200","article-title":"In vitro characterization of conditions for amyloid-\u03b2 peptide oligomerization and fibrillogenesis","volume":"278","author":"Stine","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.03.002_bib0075","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neuropharm.2011.01.051","article-title":"Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of amyloid \u03b2 oligomers on long-term potentiation (LTP) in murine hippocampal slices","volume":"60","author":"Rammes","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.03.002_bib0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jneumeth.2010.05.001","article-title":"An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies","volume":"190","author":"Ryan","year":"2010","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.tips.2013.03.002_bib0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neurobiolaging.2008.04.003","article-title":"Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons","volume":"31","author":"Shughrue","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.tips.2013.03.002_bib0090","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1523\/JNEUROSCI.1676-11.2012","article-title":"Neutralization of soluble, synaptotoxic amyloid \u03b2 species by antibodies is epitope specific","volume":"32","author":"Zago","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-60761-744-0_2","article-title":"Preparing synthetic A\u03b2 in different aggregation states","volume":"670","author":"Stine","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tips.2013.03.002_bib0100","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1471-4159.2005.03407.x","article-title":"Globular amyloid \u03b2-peptide1\u201342 oligomer \u2013 a homogeneous and stable neuropathological protein in Alzheimer's disease","volume":"95","author":"Barghorn","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2013.03.002_bib0105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1523\/JNEUROSCI.4771-07.2008","article-title":"Amyloid \u03b2 oligomers (A\u03b21\u201342 globulomer) suppress spontaneous synaptic activity by inhibition of P\/Q-type calcium currents","volume":"28","author":"Nimmrich","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1471-4159.2011.07389.x","article-title":"A monoclonal antibody against synthetic A\u03b2 dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting A\u03b2","volume":"119","author":"O\u2019Nuallain","year":"2011","journal-title":"J. Neurochem."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2013.03.002_bib0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2011.07478.x","article-title":"Soluble A\u03b2 oligomer production and toxicity","volume":"120","author":"Larson","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2013.03.002_bib0120","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm1234","article-title":"Amyloid \u03b2 protein immunotherapy neutralizes A\u03b2 oligomers that disrupt synaptic plasticity in vivo","volume":"11","author":"Klyubin","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2013.03.002_bib0125","doi-asserted-by":"crossref","first-page":"10311","DOI":"10.1074\/jbc.M608207200","article-title":"Small molecule inhibitors of aggregation indicate that amyloid \u03b2 oligomerization and fibrillization pathways are independent and distinct","volume":"282","author":"Necula","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.03.002_bib0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nbd.2008.01.010","article-title":"A\u03b2-globulomers are formed independently of the fibril pathway","volume":"30","author":"Gellerman","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2013.03.002_bib0135","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1006\/jmbi.2001.4970","article-title":"Identification and characterization of key kinetic intermediates in amyloid \u03b2-protein fibrillogenesis","volume":"312","author":"Kirkitadze","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tips.2013.03.002_bib0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1073\/pnas.222681699","article-title":"Amyloid \u03b2-protein (A\u03b2) assembly: A\u03b240 and A\u03b242 oligomerize through distinct pathways","volume":"100","author":"Bitan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.03.002_bib0145","doi-asserted-by":"crossref","first-page":"29639","DOI":"10.1074\/jbc.R800016200","article-title":"Structural classification of toxic amyloid oligomers","volume":"283","author":"Glabe","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.03.002_bib0150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.neuroscience.2007.10.054","article-title":"Plaque-bearing mice with reduced levels of oligomeric amyloid-\u03b2 assemblies have intact memory function","volume":"151","author":"Lesn\u00e9","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2013.03.002_bib0155","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1073\/pnas.0811698106","article-title":"Oligomeric amyloid \u03b2 associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques","volume":"106","author":"Koffie","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.03.002_bib0160","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.expneurol.2009.09.001","article-title":"Oligomers of amyloid \u03b2 are sequestered into and seed new plaques in the brains of an AD mouse model","volume":"223","author":"Gaspar","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2013.03.002_bib0165","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.1523\/JNEUROSCI.23-26-08844.2003","article-title":"In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-\u03b2 metabolism and half-life","volume":"23","author":"Cirrito","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-4-19","article-title":"Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575","volume":"4","author":"Garcia-Alloza","year":"2009","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.tips.2013.03.002_bib0175","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1371\/journal.pmed.0020355","article-title":"Persistent amyloidosis following suppression of A\u03b2 production in a transgenic model of Alzheimer disease","volume":"2","author":"Jankowsky","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.tips.2013.03.002_bib0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/ar050063s","article-title":"Elucidating amyloid \u03b2-protein folding and assembly: a multidisciplinary approach","volume":"39","author":"Teplow","year":"2006","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.tips.2013.03.002_bib0185","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0006-3495(94)80591-0","article-title":"Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths","volume":"67","author":"Snyder","year":"1994","journal-title":"Biophys. J."},{"key":"10.1016\/j.tips.2013.03.002_bib0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1756-6606-5-25","article-title":"Alzheimer's disease A\u03b2 assemblies mediating rapid disruption of synaptic plasticity and memory","volume":"5","author":"Klyubin","year":"2012","journal-title":"Mol. Brain"},{"key":"10.1016\/j.tips.2013.03.002_bib0195","doi-asserted-by":"crossref","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","article-title":"Synaptic targeting by Alzheimer's-related amyloid \u03b2 oligomers","volume":"24","author":"Lacor","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0200","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","article-title":"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A\u03b2 oligomers","volume":"29","author":"De Felice","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.tips.2013.03.002_bib0205","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1113\/jphysiol.2005.103754","article-title":"Effects of secreted oligomers of amyloid \u03b2-protein on hippocampal synaptic plasticity: a potent role for trimers","volume":"572","author":"Townsend","year":"2006","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2013.03.002_bib0210","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1523\/JNEUROSCI.1633-03.2004","volume":"24","author":"Wang","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0215","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.neurobiolaging.2009.11.007","article-title":"Cognitive effects of cell-derived and synthetically derived A\u03b2 oligomers","volume":"32","author":"Reed","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.tips.2013.03.002_bib0220","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.neuron.2006.10.035","article-title":"AMPAR removal underlies A\u03b2-induced synaptic depression and dendritic spine loss","volume":"52","author":"Hsieh","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2013.03.002_bib0225","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2013.03.002_bib0230","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"A\u03b2 oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0235","doi-asserted-by":"crossref","first-page":"33305","DOI":"10.1074\/jbc.M610390200","article-title":"Soluble A\u03b2 inhibits specific signal transduction cascades common to the insulin receptor pathway","volume":"282","author":"Townsend","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.03.002_bib0240","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/hmg\/ddr576","article-title":"A critical role for the PAR-1\/MARK\u2013tau axis in mediating the toxic effects of A\u03b2 on synapses and dendritic spines","volume":"21","author":"Yu","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2013.03.002_bib0245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/ncomms1341","article-title":"Interaction between prion protein and toxic amyloid \u03b2 assemblies can be therapeutically targeted at multiple sites","volume":"2","author":"Freir","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2013.03.002_bib0250","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nature07761","article-title":"Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers","volume":"457","author":"Lauren","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.03.002_bib0255","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1523\/JNEUROSCI.6500-10.2011","article-title":"Alzheimer's disease brain-derived amyloid-\u03b2-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein","volume":"31","author":"Barry","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0260","doi-asserted-by":"crossref","first-page":"10427","DOI":"10.1523\/JNEUROSCI.1459-11.2011","article-title":"Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice","volume":"31","author":"Cisse","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0265","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.0911829107","article-title":"Synthetic amyloid-\u03b2 oligomers impair long-term memory independently of cellular prion protein","volume":"107","author":"Balducci","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.03.002_bib0270","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","article-title":"A\u03b2 oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines","volume":"30","author":"Zempel","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0275","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.nlm.2011.08.003","article-title":"The A\u03b2 oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease","volume":"96","author":"Ferreira","year":"2012","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.tips.2013.03.002_bib0280","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1742-4658.2010.07568.x","article-title":"Amyloid oligomers: formation and toxicity of A\u03b2 oligomers","volume":"277","author":"Sakono","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.tips.2013.03.002_bib0285","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A\u03b2 oligomers \u2013 a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2013.03.002_bib0290","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.03.002_bib0295","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1073\/pnas.0409336102","article-title":"Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease","volume":"102","author":"Georganopoulou","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Suppl. 4","key":"10.1016\/j.tips.2013.03.002_bib0300","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jalz.2012.05.746","article-title":"A quantitative assay selective for amyloid oligomer species differentiates cerebrospinal fluid from Alzheimer's disease and age-matched normal","volume":"8","author":"Wolfe","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.tips.2013.03.002_bib0305","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archneur.57.1.100","article-title":"Plasma and cerebrospinal fluid levels of amyloid \u03b2 proteins 1\u201340 and 1\u201342 in Alzheimer disease","volume":"57","author":"Mehta","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tips.2013.03.002_bib0310","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1096\/fj.09-150359","article-title":"High-molecular-weight amyloid \u03b2 oligomers are elevated in cerebrospinal fluid of Alzheimer patients","volume":"24","author":"Fukumoto","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2013.03.002_bib0315","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.59.3.398","article-title":"Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease","volume":"59","author":"Delacourte","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.03.002_bib0320","series-title":"Abstracts of the 2012 Neuroscience Meeting Planner","article-title":"ACU-193: a drug candidate antibody selectively recognizing soluble A\u03b2 oligomers","author":"Krafft","year":"2012"},{"key":"10.1016\/j.tips.2013.03.002_bib0325","unstructured":"Look, G.C. et al. Acumen Pharmaceuticals. Methods of inhibiting the formation of amyloid-\u03b2 diffusible ligands using acylhydrazide compounds, WO\/2009\/009768"},{"key":"10.1016\/j.tips.2013.03.002_bib0330","series-title":"Abstracts of the 2012 Neuroscience Meeting Planner","article-title":"Receptor antagonists inhibit A\u03b2 oligomer-induced deficits","author":"Catalano","year":"2012"},{"key":"10.1016\/j.tips.2013.03.002_bib0335","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000197881","article-title":"Pathological substrates of cognitive decline in Alzheimer's disease","volume":"24","author":"Giannokopoulos","year":"2009","journal-title":"Front. Neurol. Neurosci."},{"key":"10.1016\/j.tips.2013.03.002_bib0340","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3233\/JAD-2010-101422","article-title":"Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients","volume":"23","author":"Rami","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.tips.2013.03.002_bib0345","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.tips.2013.03.002_bib0350","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain A\u03b2 burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat. Neurosci."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713000436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713000436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T04:51:03Z","timestamp":1562907063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614713000436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0165614713000436"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2013.03.002","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The case for soluble A\u03b2 oligomers as a drug target in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2013.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}